DRRX's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 189.11 -- higher than 83.62% of US-listed equities with positive expected earnings growth.
Price to trailing twelve month operating cash flow for DRRX is currently 315.29, higher than 98.97% of US stocks with positive operating cash flow.
Revenue growth over the past 12 months for Durect Corp comes in at 153.13%, a number that bests 96.25% of the US stocks we're tracking.
If you're looking for stocks that are quantitatively similar to Durect Corp, a group of peers worth examining would be EXEL, ESPR, TNAV, CRUS, and SMCI.
DRRX's SEC filings can be seen here. And to visit Durect Corp's official web site, go to www.durect.com.
DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceuticals products based on its proprietary drug formulations and delivery platform technologies in the United States, Europe, Japan, and internationally. The company was founded in 1998 and is based in Cupertino, California.
DRRX Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Durect Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Durect Corp ranked in the 4th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Durect Corp, consider:
The company's debt burden, as measured by earnings divided by interest payments, is 0.23; that's higher than only 24.31% of US stocks in the Healthcare sector that have positive free cash flow.
Durect Corp's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Durect Corp? See DRAD, AGHC, ALC, AMRN, and FGEN.
DURECT Corporation (Nasdaq: DRRX) today announced it has dosed the first patient in its randomized, double-blind, placebo-controlled, multi-center Phase 2 study to evaluate the safety and efficacy of DUR-928 in hospitalized COVID-19 patients with acute liver or kidney injury. The primary efficacy endpoint is a composite of survival and being free of acute organ failure at Day 28. The company plans to enroll approximately 80 patients in multiple study sites across the U.S.
DURECT Corporation (Nasdaq: DRRX) today announced that it will participate in the HC Wainwright 22nd Annual Global Investment Conference, Cantor Fitzgerald Virtual Global Healthcare Conference and Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.
DURECT Corporation (Nasdaq: DRRX) today announced the presentation of pharmacokinetic (PK) data from a Phase 2a study of DUR-928 in alcoholic hepatitis (AH) at the Digital International Liver Congress™ 2020 (EASL), taking place on August 27-29. DUR-928 was well tolerated at all doses tested in 19 AH patients, including 12 severe AH patients. These PK data, together with other available information for the drug, have been used to inform dose selection in the Company's upcoming Phase 2b study of DUR-298 in AH, planned to begin in the second half of 2020.